150 related articles for article (PubMed ID: 11559886)
21. [Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].
Ueyama H; Nakahashi H; Sawanishi K; Kuze M; Ono T
Hinyokika Kiyo; 1992 Dec; 38(12):1429-35. PubMed ID: 1288237
[TBL] [Abstract][Full Text] [Related]
22. Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO).
Campos A; Garin EH
Clin Pediatr (Phila); 1992 Feb; 31(2):94-9. PubMed ID: 1544282
[TBL] [Abstract][Full Text] [Related]
23. Correction of anaemia in haemodialysis patients with recombinant human erythropoietin.
Boran M; Dalva I; Yazicioğlu A; Akbay E; Cetin S
Int Urol Nephrol; 1993; 25(2):197-203. PubMed ID: 8365853
[TBL] [Abstract][Full Text] [Related]
24. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin.
Moreno F; Aracil FJ; Pérez R; Valderrábano F
Am J Kidney Dis; 1996 Apr; 27(4):548-56. PubMed ID: 8678066
[TBL] [Abstract][Full Text] [Related]
25. Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure.
Metra M; Cannella G; La Canna G; Guaini T; Sandrini M; Gaggiotti M; Movilli E; Dei Cas L
Am J Cardiol; 1991 Oct; 68(10):1060-6. PubMed ID: 1927920
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
Mohini R
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
[TBL] [Abstract][Full Text] [Related]
27. [Erythropoietin--the first hematologic hormone in clinical use].
Rhyner K
Schweiz Med Wochenschr; 1988 Mar; 118(11):375-80. PubMed ID: 3287601
[TBL] [Abstract][Full Text] [Related]
28. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
29. Optimal hematocrit in patients on dialysis therapy.
Nissenson AR
Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S142-6. PubMed ID: 9892381
[TBL] [Abstract][Full Text] [Related]
30. Therapy of renal anemia with recombinant human erythropoietin in children with end-stage renal disease.
Scigalla P; Bonzel KE; Bulla M; Burghard R; Dippel J; Geisert J; Leumann E; von Lilien T; Müller-Wiefel DE; Offner G
Contrib Nephrol; 1989; 76():227-40; discussion 240-1. PubMed ID: 2684524
[No Abstract] [Full Text] [Related]
31. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human erythropoietin correction of anemia. Dialysis efficiency, waste retention, and chronic dose variables.
Paganini EP; Abdulhadi MH; Garcia J; Magnusson MO
ASAIO Trans; 1989; 35(3):513-5. PubMed ID: 2688718
[TBL] [Abstract][Full Text] [Related]
33. [A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis].
Fernández-Gallego J; Gutiérrez C
Nefrologia; 2003; 23(2):177-8. PubMed ID: 12778885
[No Abstract] [Full Text] [Related]
34. Clinical and blood rheologic stability in erythropoietin-treated predialysis patients.
Brown CD; Friedman EA
Am J Nephrol; 1990; 10 Suppl 2():29-33. PubMed ID: 2260615
[TBL] [Abstract][Full Text] [Related]
35. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
[TBL] [Abstract][Full Text] [Related]
36. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
[TBL] [Abstract][Full Text] [Related]
37. Use of low-dose subcutaneous recombinant human erythropoietin in end-stage renal disease: experience with children receiving continuous cycling peritoneal dialysis.
Ongkingco JR; Ruley EJ; Turner ME
Am J Kidney Dis; 1991 Oct; 18(4):446-50. PubMed ID: 1928063
[TBL] [Abstract][Full Text] [Related]
38. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group.
Am J Kidney Dis; 1991 Jul; 18(1):50-9. PubMed ID: 2063855
[TBL] [Abstract][Full Text] [Related]
39. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
Sinnassamy P; Andre JL; Treize G; Leroy B
Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412
[TBL] [Abstract][Full Text] [Related]
40. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model.
Messana JM; Chuang CC; Turenne M; Wheeler J; Turner J; Sleeman K; Tedeschi P; Hirth R
Am J Kidney Dis; 2009 Mar; 53(3):503-12. PubMed ID: 19185402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
